Pfizer reports ‘positive’ results from Phase 3 MagnetisMM-5 study

Pfizer (PFE) announced positive topline results from the Phase 3 MagnetisMM-5 study evaluating ELREXFIO as monotherapy in adults with relapsed or refractory multiple myeloma (RRMM) who received at least one prior line of treatment. The study demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival, as assessed by blinded independent central review, versus standard-of-care daratumumab plus pomalidomide and dexamethasone. The safety and tolerability of ELREXFIO was consistent with its known safety profile. The PFS results exceeded the pre-specified interim analysis target hazard ratio for efficacy, with most ELREXFIO-treated patients remaining progression-free. The trial remains ongoing to assess overall survival, a key secondary endpoint, which was not yet mature at the time of this interim analysis. These data will be discussed with global health authorities, and detailed results from MagnetisMM-5 will be submitted for presentation at a future medical congress.